Trametinib is indicated as a single agent or in combination with dabrafenib for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, for the adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma, and in combination with dabrafenib for the treatment of BRAF V600E-mutant unresectable or metastatic non-small cell lung cancer. In combination with dabrafenib, it is indicated for the treatment of BRAF V600E-mutant locally advanced or metastatic anaplastic thyroid cancer (ATC) in adults who have no satisfactory locoregional treatment options. In combination with dabrafenib, it is indicated for use in combination with dabrafenib for the treatment of unresectable or metastatic BRAF V600E-mutated solid tumors in patients who have progressed after prior therapy and have no satisfactory alternative treatment options.
The recommended dose of trametinib for adult patients is 2 mg orally once daily. The recommended dose of trametinib in pediatric patients is based on body weight. Take trametinib at least 1 hour before or 2 hours after a meal. Treatment duration was until disease progression or unacceptable toxicity. Recommended dosage for adverse reactions in adult patients is first dose reduction: 1.5 mg PO once daily, second dose reduction: 1 mg PO once daily, subsequent modifications: If 1 mg PO once daily is not tolerated, permanently discontinue treatment. Recommended dose reduction for adverse reactions in pediatric patients: If the dose is 2 mg PO once daily: Dose reduction is the same as in adult patients. If the dose is 1.5 mg PO once daily: First dose reduction: 1 mg PO once daily, Second dose reduction: 0.5 mg PO once daily, subsequent modifications: If up to two dose reductions are not tolerated, permanently discontinue. If the dose is 1 mg once daily: First dose reduction: 0.5 mg PO once daily, Second dose reduction: Permanently discontinue. Mild (CrCl 60 to less than 90 ml/min) to moderate (CrCl 30 to less than 60 ml/min): no adjustment is recommended, severe (CrCl 15 to less than 30 ml/min): use with caution, end-stage renal disease (CrCl less than 15 ml/min): no data. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.
.jpeg)
